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Background: In previous studies, we identiﬁed two urinary proteomic classiﬁers, termed HF1 and HF2, which
discriminated subclinical diastolic left ventricular (LV) dysfunction from normal. HF1 and HF2 combine informa-
tion from 85 and 671 urinary peptides, mainly up- or down-regulated collagen fragments.We sought to validate
these classiﬁers in a population study.
Methods: In 745 people randomly recruited from a Flemish population (49.8 years; 51.3%women), wemeasured
early and late diastolic peak velocities of mitral inﬂow (E and A) and mitral annular velocities (e' and a') by
conventional and tissue Doppler echocardiography, and the urinary proteome by capillary electrophoresis
coupled with mass spectrometry.
Results: In the analyses adjusted for sex, age, bodymass index, blood pressure, heart rate, LVmass index and intake
ofmedications, we expressed effect sizes per 1-SD increment in the classiﬁers. HF1was associatedwith 0.204 cm/s
lower e' peak velocity (95% conﬁdence interval, 0.057–0.351; p= 0.007) and 0.145 higher E/e' ratio (0.023–0.268;
p = 0.020), while HF2 was associated with a 0.174 higher E/e' ratio (0.046–0.302; p = 0.008). According to
published deﬁnitions, 67 (9.0%) participants had impaired LV relaxation and 96 (12.9%) had elevated LV ﬁlling
pressure. The odds of impaired relaxation associated with HF1 was 1.38 (1.01–1.88; p = 0.043) and that of
increased LV ﬁlling pressure associated with HF2 was 1.38 (1.00–1.90; p= 0.052).
Conclusions: In a general population, the urinary proteome correlated with diastolic LV dysfunction, proving its
utility for early diagnosis of this condition.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Recent guidelines [1,2] describe heart failure (HF) as a complex clin-
ical syndrome that results from any structural or functional impairment
of ventricularﬁlling or ejection of blood. HFmay result fromdisorders of
the pericardium, myocardium, endocardium, heart valves, or great
vessels or from certain metabolic abnormalities, but most HF patients
have symptoms due to impaired left ventricular (LV) myocardial func-
tion with or without preserved ejection fraction. Impaired LV function
evolves from asymptomatic changes in cardiac structure (e.g. LV hyper-
trophy) and function (e.g. impaired relaxation) into clinically overt HF,re, Research Unit Hypertension
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eland Ltd. This is an open access ardisability and death. The 5-year mortality rate of symptomatic HF is ap-
proximately 60% [3]. Diastolic HF is characterised by slow LV relaxation,
increased LV stiffness, increased interstitial deposition of collagen, and
modiﬁed extracellular matrix proteins [4]. Diastolic HF accounts for
40–50% of all HF cases and has a prognosis as ominous as systolic HF
[4]. In randomly recruited European population samples, the frequency
of asymptomatic echocardiographically diagnosed diastolic LV dysfunc-
tion (early stage) is as high as 27% [5,6]. This constitutes a large pool of
subjects at high risk of diastolic HF.
The pathogenesis underlying diastolic LV dysfunction might rest on
atherosclerosis of the large epicardial or intramural coronary arteries
[7,8]. More recently experts in the ﬁeld advanced the hypothesis that en-
dothelial dysfunction in the coronary microcirculation and a systemic
pro-inﬂammatory state favour the development of LV hypertrophy, stiff-
ening of cardiomyocytes and interstitialmyocardialﬁbrosis [9,10].What-
ever the underlying mechanism, modiﬁcation in the extracellular
myocardial matrix and collagen turnover are hallmarks of diastolic LV
dysfunction. In line with this concept, we identiﬁed in a preliminaryticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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collagen fragments, that discriminated between19hypertensive patients
with asymptomatic diastolic LV dysfunction and 19 controls [11]. With
adjustments applied for multiple testing three urinary peptide bio-
markers remained signiﬁcant [11]. In an attempt to ﬁndways to facilitate
the diagnosis of asymptomatic diastolic LV dysfunction, we evaluated in
a Flemish population sample the association of diastolic LV function,
analysed as a continuous or categorical variable, with urinary proteomic
biomarkers combined in a high-dimensional model (classiﬁer).
2. Material and methods
2.1. Participants
The Ethics Committee of the University of Leuven approved the Flemish Study on
Environment, Genes and Health Outcomes (FLEMENGHO) [12,13]. Our study was
designed to enrol a randompopulation samplewith families as the sampling unit. Recruit-
ment started in 1985 [13]. The initial participation rate was 78.0%.
FromMay 2005 until May 2010, wemailed an invitation letter to 1208 former partic-
ipants for a re-examination, including echocardiography. However, 153 former partici-
pants were unavailable for follow-up, because they had died (n= 26), because they had
been institutionalised or were too ill (n = 27), or because they had moved out of the
area (n= 100). Of the remaining 1055 former participants, 828 renewed informed con-
sent. The participation rate for the re-examination was therefore 78.5%. We excluded
from analysis 19 cases and 19 controls, because they had been selected to identify one
of the multidimensional classiﬁers used in the current analyses [11]. Furthermore, we
removed an additional 45 participants from analysis, because no urine sample was avail-
able for urinary proteomics (n= 22), because of atrial ﬁbrillation (n= 8) or paced heart
rhythm (n = 3), because their LV mass (n = 6) or diastolic LV function could not be
reliably determined (n = 6). Thus, the number of participants included in the current
cross-sectional analysis totalled 745.
2.2. Echocardiography
2.2.1. Data acquisition
One experienced physician (T.K.) did the ultrasound examination [5], using a Vivid7
Pro (GE Vingmed, Horten, Norway) interfaced with a 2.5- to 3.5-MHz phased-array
probe. For off-line analysis, she recorded at least ﬁve heart cycles according to the recom-
mendations of the American Society of Echocardiography [14]. M-mode echocardiograms
of the LVwere recorded from the parasternal long-axis view under control of the 2-dimen-
sional image. The ultrasound beamwas positioned just below the mitral valve at the level
of theposterior tendinous chords. To recordmitral andpulmonary vein (PV)ﬂowvelocities
from the apical window, the observer positioned the Doppler sample volume at themitral
valve tips, in the right superior PV, and between the LV outﬂow andmitral inﬂow, respec-
tively. From the apical window, the observer positioned a 5-mm Doppler sample at the
septal, lateral, inferior and posterior sites of the mitral annulus to record low-velocity,
high-intensitymyocardial signals at a high frame rate (N190 frames per second), while en-
suring parallel alignment of the ultrasound beamwith themyocardial segment of interest.
2.2.2. Off-line analysis
One reader (T.K.) analysed the digitally stored images, averaging three heart cycles,
using a workstation running EchoPac software, version 4.0.4 (GE Vingmed, Horten,
Norway). LV internal diameter and interventricular septal and posterior wall thickness
were measured at end-diastole from the 2-dimensionally guided M-mode tracing. When
optimal orientation of M-mode ultrasound beam could not be obtained, the reader per-
formed linear measurements on correctly oriented 2-dimensional images. End-diastolic
LV dimensions were used to calculate LV mass by an anatomically validated formula [14].
Left atrial (LA) volume was calculated using the prolate-ellipsoid method from the LA di-
mensions in three orthogonal planes and indexed to body surface area [14]. From the
transmitral ﬂow signal, the reader determined peak early diastolic velocity (E), peak late di-
astolic velocity (A), the E/A ratio, and transmitral A ﬂow duration. From the PV ﬂow signal,
she measured the duration of PV reversal ﬂow during atrial systole (AR). From the TDI re-
cordings, the readermeasured peak early (e') and peak late (a') diastolic mitral annular ve-
locities, and the e'/a' ratio at the four acquisition sites (septal, lateral, inferior, and posterior).
2.2.3. Reproducibility
Intra-observer reproducibility was the 2-SD interval about the mean of the relative
differences across pairwise readings. As reported previously [5], the intra-observer repro-
ducibility for the tissue Doppler peak velocities across the four sampling sites ranged from
4.48% to 5.34% for e' and from 3.96% to 4.52% for a'. For the LV internal end-diastolic diam-
eter, reproducibility was 4.6% for LV wall thickness and 4.3% for LV mass [15].
2.2.4. Classiﬁcation of diastolic LV function
For staging LV diastolic dysfunction, the mitral inﬂow and TDI velocities were
combined, as previously described [5,6]. The ﬁrst group included patients with an abnor-
mally low age-speciﬁc transmitral E/A ratio indicative of impaired relaxation, but without
evidence of increased LV ﬁlling pressures (E/e' ≤8.5). The second group had mildly-to-
moderately elevated LV ﬁlling pressure (E/e' N8.5) and an E/A ratio within the normal
age-speciﬁc range. Differences in durations between the transmitral A ﬂow and thereverse PV ﬂow during atrial systole (Ad b ARd + 10) and/or LA volume index
(≥28 mL/m2) were checked to conﬁrm possible elevation of the LV ﬁlling pressures in
group 2. The third group had an elevated E/e' ratio and an abnormally low age-speciﬁc
E/A ratio (combined dysfunction).
2.3. Urinary proteomics
Participants collected 24-h urine samples within 1 week of the echocardiographic
examinations. Using 24-h urine samples rather than spot urine samples minimises the
small but detectable inﬂuence of food intake [16] during the day on the urinary proteome.
Aliquots were stored at−80 °C. Urine (0.7 mL) was thawed immediately before analysis
and dilutedwith 0.7mL of 2Murea, 10mMNH4OH containing 0.02% SDS [17]. To remove
higher molecular mass proteins, such as albumin and immunoglobulin G, the sample was
ultra-ﬁltered using Centrisart ultracentrifugation devices (20 kDa MWCO; Sartorius,
Göttingen, Germany) at 3000 g relative centrifugal force until 1.1mL of ﬁltratewas obtain-
ed. This ﬁltrate was then applied onto a PD-10 desalting column (GE Healthcare, Uppsala,
Sweden) equilibrated in 0.01% NH4OH in HPLC-grade H2O (Roth, Germany) to decrease
matrix effects by removing urea, electrolytes, and salts, and to enrich polypeptides. Finally,
all samples were lyophilised, stored at 4 °C, and suspended in HPLC-grade H2O shortly
before CE–MS analyses [18].
CE–MS analyses were performed using a P/ACEMDQ capillary electrophoresis system
(Beckman Coulter, Fullerton, USA) on-line coupled to a micrOTOF MS (Bruker Daltonic,
Bremen, Germany) [18]. The ESI sprayer (Agilent Technologies, Palo Alto, CA, USA) was
grounded, and the ion spray interface potential was set between−4 and−4.5 kV. Data
acquisition and mass spectrometry acquisition methods were automatically controlled
by the capillary electrophoresis via contact-close-relays. Spectra were accumulated
every 3 s, over a range of charge states (m/z) 350 to 3000. Previous publications described
the accuracy, precision, selectivity, sensitivity, reproducibility, and stability of the CE–MS
measurements in detail [19].
Mass spectra were processed using MosaiquesVisu software, including peak picking,
deconvolution and de-isotoping [20]. Migration time and peak intensity were normalised
using internal polypeptide standards [21]. These fragments result from normal biological
processes and appear to be unaffected by any disease state studied to date based on
over 20,000 samples in the Mosaiques database [22]. The resulting peak list characterises
each polypeptide by its molecular mass, normalised capillary electrophoresis migration
time, and normalised signal intensity. All detected polypeptideswere deposited, matched,
and annotated in a Microsoft SQL database, allowing further analysis and comparison of
multiple patient groups.
Peptide fragments identiﬁed in previous studies were combined into a single summa-
ry variable, using the support-vector machine based MosaCluster software, version 1.6.5.
In the present study, we used two high-dimensional classiﬁers. As published previously
[11], HF1 combined information from 85 peptide fragments identiﬁed in 19 patients
with diastolic LV dysfunction and 19 controls. To generate the HF2 classiﬁer, all urinary
proteomic datasets from cases available in the Mosaiques database [22] were combined
and compared with data from sex- and age-matched controls. Cases were 98 patients
with LV diastolic dysfunction recruited from our population [11] (n = 35) or admitted
to the hospital because of overt HF (n = 63). The patients with overt HF were all on
multiple drugs, included 49.2% women and were 67.1 ± 9.9 years old. The underlying
cause of HF was ischaemic cardiomyopathy (50.8%), dilated cardiomyopathy (28.6%),
hypertrophic cardiomyopathy (1.6%), valvular heart disease (1.6%) or unspeciﬁed
(17.4%). Comparing cases with controls identiﬁed 710 potential biomarkers, based on a
p-value of less than 0.05 with adjustment for multiple testing applied. Using a take-one-
out procedure [23] to remove potential biomarkers that are of no apparent value, the
number of biomarkers was reduced to 671. A MosaiquesVisu software based classiﬁer
including these 671 urinary peptides was developed, using all 196 (98 cases and 98
controls) datasets. Upon complete take-one-out cross-validation, in the training dataset,
the classiﬁer had 88.7% accuracy, 87.8% sensitivity, and 89.58% speciﬁcity. Full information
of the polypeptides making up the two classiﬁers (Tables S1 and S2) and on the polypep-
tides with known amino-acid sequence (Tables S3 and S4) is available in the Supplemen-
tary material online. A subset of 671 participants had plasma NT-proBNP measured by a
competitive enzyme immunoassay developed for research purposes only use (Biomedica
Gruppe, Vienna, Austria) [24].
2.4. Other measurements
At the examination centre, nurses administered a questionnaire to collect detailed
information on eachparticipant'smedical history, smoking and drinking habits, and intake
of medications. The conventional blood pressure was the average of ﬁve consecutive
auscultatory readings obtained with the subject in the seated position. Hypertension
was a blood pressure of at least 140mmHg systolic or 90mmHg diastolic or use of antihy-
pertensive drugs. Body mass index was weight in kilogrammes divided by the square of
height in metres. Participants fasted for 6 h or longer prior to venepuncture. Venous
blood samples were analysed for glucose, creatinine, total and high-density (HDL) choles-
terol, and γ-glutamyltransferase as index of alcohol intake. We computed low-density
(LDL) cholesterol, using Friedewald's formula [25]. We applied the Modiﬁcation of Diet
in Renal Disease Study Group equation (MDRD) to estimate the glomerular ﬁltration
rate (eGFR) from sex, age, and serum creatinine [26]. Diabetes mellitus was a self-
reported diagnosis, a fasting glucose level of at least 126 mg/dL, or use of antidiabetic
agents [27]. In 671 participants, NT-proBNP was measured in plasma by a competitive
enzyme immunoassay (EIA) for research use (Biomedica Gruppe, Vienna, Austria).
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Fig. 1. Distribution of the urinary multi-dimensional biomarkers HF1 (A) and HF2 (B) in
745 participants. S and K are the coefﬁcients of skewness and kurtosis, respectively. The
p-value is for the Kolmogorov–Smirnov test and indicates departure of the actually ob-
served distribution (full line) from normality (dotted line).
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micro-albuminuria. Micro-albuminuria was a 24-h urinary excretion ranging from 30 to
300 mg and macro-albuminuria a 24-h excretion exceeding 300 mg.
2.5. Statistical analysis
For databasemanagement and statistical analysis,weused the SAS system, version 9.3
(SAS Institute Inc., Cary, NC). Signiﬁcance was a two-tailed α-level of 0.05 or less. Means
were compared using the large-sample z-test or ANOVA and proportions by Fisher's
exact test. The distribution of γ-glutamyltransferase was normalised by a logarithmic
transformation. Our statistical methods also included multivariable-adjusted linear and
logistic regression analysis with as dependent variables LV mass, the indexes reﬂecting
diastolic LV function or the categories of diastolic LV dysfunction. The covariables
accounted for in all analyses were sex, age, body mass index, mean arterial pressure,
heart rate, LV mass index, treatment with inhibitors of the renin system (angiotensin-
converting enzyme inhibitors or angiotensin II type-1 receptor blockers), and use of
β-blockers. In sensitivity analyses, models were additionally adjusted for blood
glucose, serum creatinine and γ-glutamyltransferase as index of alcohol intake. To
maximise the discriminatory accuracy of HF1 and HF2, we maximised Younden's
index (sensitivity + speciﬁcity − 1) in unadjusted logistic models. Finally, we
assessed the added capacity of the urinary proteomic biomarkers to differentiate
normal from abnormal diastolic LV function, using the integrated discrimination
improvement (IDI) and the net reclassiﬁcation improvement (NRI) [28].
2.6. Role of the funding source
The funding source had no role in the study design, data extraction, data analysis, data
interpretation, or writing of the report. The corresponding author had full access to all the
data in the study and had the responsibility for the decision to submit for publication.
3. Results
3.1. General characteristics of participants
Women (n = 382) and men (n = 363) had similar age (mean,
49.8 years; range, 18 to 89 years). The study sample included 309
(41.5%) hypertensive patients of whom 185 (59.9%) were on antihyper-
tensive drug treatment, and 9 participants (1.2%) had diabetes mellitus.
Among the 185 patients on treatment with antihypertensive drugs, 64
(34.6%) used inhibitors of the renin system (angiotensin converting
enzyme inhibitors or angiotensin II type-1 receptor blockers), and 109
(58.9%) were on treatment with β-blockers. Of 382 women and 363
men, 74 (19.4%) women and 74 (20.4%) men were smokers, and 214
(56.0%) women and 301 (82.9%) men reported intake of alcohol. In
smokers, median tobacco use was 15 cigarettes per day (interquartile
range, 7 to 20 cigarettes per day). In drinkers, the median alcohol
consumption was 10 g per day (interquartile range, 4 to 17 g per day).
Only one participant had a history of HF. Thirty patients had mild to
moderate valvular heart disease, including, aortic stenosis (n = 3),
aortic regurgitation (n = 6), mitral regurgitation (n = 10), tricuspid
regurgitation (n = 2), or a combinations thereof. One participant had
Marfan syndrome. The prevalence of micro- and macro-albuminuria
in our study population was 26 (3.5%) and 3 (0.4%), respectively.
3.2. Analyses across categories of HF1 and HF2
Fig. 1 shows the distributions of HF1 and HF2. Table 1 lists the
characteristics of participants by fourths of the distribution of HF1.
Age, body mass index, blood pressure, the prevalence of hypertension
and use of antihypertensive drugs, LDL cholesterol, blood glucose,
serum creatinine and γ-glutamyltransferase increased (p ≤ 0.049)
with higher HF1 category, whereas the opposite was the case for HDL
cholesterol and eGFR (p ≤ 0.049). In the subset 671 participants who
had NT-proBNP measured, the geometric mean level was 203.8 pmol/L
(interquartile range, 140.1 to 287.3 pmol/L). The NT-proBNP levels did
not increase with higher categories of HF1 (Table 1) and HF2 (Table S5).
HF2 (r= 0.10; p= 0.009), but not HF1 (r= 0.02; p= 0.65) correlated
with the logarithmically transformed NT-proBNP level.
Table 2 shows that LA volume, LA volume index, LV mass, LV mass
index, deceleration time, isovolumetric relaxation time, A and a' peak
velocities, and the E/e' ratio increased (p ≤ 0.0007) with higher HF1category, whereas the opposite was the case (p b 0.0001) for the E
and e' peak velocities and the E/A and e'/a' ratios. Findings were similar
across fourths of the HF2 distribution for the characteristics of the
participants (Table S5) as well as for the echocardiographic measure-
ments (Table S6). Additional information on the risk factor scores and
comorbidities by fourths of the distributions of HF1 and HF2 are provid-
ed in Table S7.
3.3. Multivariable-adjusted analyses of continuous echocardiographic
measures
With adjustments applied for sex, age, body mass index, mean arte-
rial pressure, heart rate, LV mass index, treatment with inhibitors of
the renin system, and use of β-blockers, as shown in Table 3, a 1-SD in-
crement in HF1 was associated with a 0.908 mL decrease in LA volume,
a 0.473mL/m2 lower LA volume index, a 0.204 cm/s lower e' peak veloc-
ity (p = 0.007), a 2.512 (p = 0.049) longer deceleration time and a
0.145 higher E/e' ratio (p = 0.020). With similar adjustments, a 1-SD
increment in HF2was associated with a 3.971 (p= 0.003) longer decel-
eration time, a 0.174 higher E/e' ratio (p = 0.008), a 0.025 higher E/A
ratio (p= 0.037), and a 0.152 cm/s lower a' peak velocity (p= 0.008).
The association between the E/A ratio and HF2 was driven by patients
with increased LV ﬁlling pressure. After removal of these 96 patients,
the association size weakened to 0.014 (95% conﬁdence interval,
−0.013 to 0.041; p = 0.31). LV mass and the other Doppler indexes
were not signiﬁcantly associated with HF1 (0.091 ≤ p ≤ 0.93) or HF2
(0.22 ≤ p ≤ 0.82). As shown in Table S8, analyses of the Doppler
measurements additionally adjusted for blood glucose, serum creatinine
and γ-glutamyltransferase were conﬁrmatory.
3.4. Multivariable-adjusted odds ratios for of diastolic LV dysfunction
According to the deﬁnitions given in the methods and in previous
publications [5,6] 67 (9.0%) participants had impaired LV relaxation,
80 (10.7%) had elevated LV ﬁlling pressure, and 16 (2.1%) had a
combined dysfunction. To allow a multivariable analysis, we pooled
Table 1
Patient characteristics by fourths of the distribution of HF1.
Characteristic Categories of the urinary HF1 biomarker P
Limits, score b−1.639 −1.639 to−1.078 −1.077 to−0.489 ≥−0.488
Number of subjects (%)
All patients in category 187 187 185 186
Women 96 (51.3) 96 (51.3) 101 (54.6) 89 (47.9) 0.64
Smokers 47 (25.1) 37 (19.8) 34 (18.4) 30 (16.1) 0.16
Drinking alcohol 135 (72.2) 131 (70.1) 123 (66.5) 126 (67.7) 0.64
Hypertension 53 (28.3) 62 (33.2) 78 (42.2) 116 (62.4)§ b0.0001
Antihypertensive treatment 25 (13.4) 29 (15.5) 44 (23.8)* 87 (46.8) § b0.0001
Diabetes mellitus 3 (1.6) 0 1 (0.5) 5 (2.7) 0.084
Mean (SD) of characteristic
Age, years 44.4 ± 14.5 47.3 ± 15.3 50.9 ± 14.5* 56.7 ± 14.8‡ b0.0001
Body mass index, kg/m2 25.4 ± 3.7 25.8 ± 3.7 26.5 ± 4.4 27.8 ± 4.7† b0.0001
Ofﬁce blood pressure
Systolic pressure, mmHg 125.6 ± 14.7 127.7 ± 18.6 129.3 ± 17.9 132.5 ± 17.3 0.001
Diastolic pressure, mmHg 78.7 ± 9.1 78.7 ± 10.2 80.4 ± 9.2 80.8 ± 9.5 0.049
Mean arterial pressure, mmHg 94.3 ± 9.8 95.0 ± 11.3 96.7 ± 10.8 98.0 ± 10.5 0.003
Heart rate, beats per minute 61.1 ± 9.2 60.4 ± 9.6 60.4 ± 9.7 61.2 ± 10.7 0.79
Biochemical data
Total cholesterol, mmol/L 5.09 ± 0.96 5.27 ± 0.97 5.30 ± 0.95 5.29 ± 1.01 0.11
HDL cholesterol, mmol/L 1.46 ± 0.35 1.44 ± 0.34 1.44 ± 0.37 1.37 ± 0.35* 0.049
LDL cholesterol, mmol/L 3.05 ± 0.87 3.23 ± 0.85* 3.23 ± 0.84 3.24 ± 0.87 0.042
Blood glucose, mmol/L 4.86 ± 0.55 4.82 ± 0.50 4.95 ± 0.68* 5.15 ± 1.23 0.0003
Serum creatinine, μmol/L 81.7 ± 13.2 82.2 ± 13.3 83.2 ± 13.7 87.1 ± 20.4* 0.003
eGFR, mL/min/1.73 m2 84.4 ± 14.8 83.5 ± 19.0 79.6 ± 14.4* 76.5 ± 16.7 b0.0001
γ-glutamyltransferase, units/L 21 (12–37) 22 (12–59) 23 (11–48) 26 (13–61)* 0.003
NT-proBNP, pmol/L 211 (109–424) 193 (87–399) 211 (92–424) 200 (100–399) 0.42
Abbreviations: eGFR, estimated glomerular ﬁltration rate calculated according to the MDRD formula, as described in reference 5510. Ofﬁce blood pressure was the average of ﬁve
consecutive readings. Heart rate was determined during the echocardiographic examination. Hypertensionwas an ofﬁce blood pressure of≥140 mmHg systolic, or≥90 mmHg diastolic,
or use on antihypertensive drugs. For γ-glutamyltransferase and NT-proBNP, values are geometric mean (interquartile range). NT-proBNP was measured in 167, 167, 166 and 171
participants of the 1st, 2nd, 3rd and 4th quartile, respectively (671 in total). P values denote the signiﬁcance of the differences in prevalence rates or means across fourths of the HF1
distribution. Signiﬁcance of the difference with the adjacent lower fourth: * p ≤ 0.05; † p ≤ 0.01; ‡ p ≤ 0.001; § p b 0.0001.
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combined LV dysfunction. With adjustments applied for sex, age,
body mass index, mean arterial pressure, heart rate, LV mass index,
treatment with inhibitors of the renin system, and use of β-blockers,
as shown in Table 4 and Fig. S1, a 1-SD increment in HF1 was associ-
ated with a 38% higher risk of impaired relaxation (p = 0.043), but
not with a signiﬁcantly elevated risk of having an elevated LV ﬁlling
pressure (odds ratio, 1.20; p = 0.24). A 1-SD increment in HF2 was
weakly associated with a 38% higher risk of increased LV ﬁlling
pressure (p = 0.052), but not with impaired relaxation (odds ratio,
1.24; p= 0.22). As shown in Table S9, analyses additionally adjusted
for blood glucose, serum creatinine and γ-glutamyltransferase were
conﬁrmatory.
3.5. Improvement of diagnostic accuracy
Bymaximizing Younden's index, we determined optimal thresholds
for HF1 and HF2 to differentiate normal from abnormal left diastolic LV
function. Sensitivity of the optimised thresholds ranged from 65.6% to
93.8% and speciﬁcity from 31.1% to 66.3% (Table S10). For detecting
any form of diastolic LV dysfunction, either impaired relaxation,
increased ﬁlling pressure or both (Table S11), both HF1 and HF2 signif-
icantly (p≤ 0.003) enhanced NRI, but not IDI (p≥ 0.12) except for HF1
in the diagnosis of increased ﬁlling pressure (p= 0.032).
4. Discussion
The keyﬁnding of our studywas that in a general population diastol-
ic LV function correlated with multidimensional urinary proteomic
classiﬁers. Our current ﬁndings extent those of a previously published
case–control study [11]. In 19 asymptomatic hypertensive patients
and 19matched controls, we identiﬁed a set of 85 urinary polypeptides
that discriminated diastolic LV dysfunction from normal LV function
[11]. A subsequent replication study in 16 hypertensive patients and16 controls conﬁrmed the diagnostic accuracy of the set urinary pep-
tides [11]. However, Redﬁeld and colleagues demonstrated that
among people with moderate or severe diastolic or systolic dysfunc-
tion, less than half had recognised congestive heart failure [29]. In
multivariable-adjusted analyses, both mild and moderate or severe
diastolic LV dysfunction predicted all-cause mortality over a median
follow-up of 3.5 years [29]. The Olmsted County study [29], taken
together with our current observations, suggest that the urinary
proteome is a harbinger of clinical manifestations occurring later
during the course of the disease.
Deﬁning diagnostic thresholds for conditions, such as diastolic
LV dysfunction, should be based on a randomly selected non-
institutionalised sample of the general population [30,31]. To classify di-
astolic LV function,we ﬁrst selected a healthy subsample from a Flemish
population without history of cardiovascular disease and with low risk
cardiovascular proﬁle. In this reference group we determined age-
speciﬁc cut-off points for the indexes of diastolic LV function, including
E/e', E/A ratio, left atrial volume indexed to body surface area, and
Δ(Ad–ARd). Next, we demonstrated that these indexes were consistent
and reproducible in FLEMENGHO [5] and in population cohorts [6] en-
rolled in the European Project on Genes in Hypertension (EPOGH). For
instance, the 97.5th percentiles of E/e' ratio in the FLEMENGHO [5]
and EPOGH [6] reference groups were 8.6 and 8.5, respectively. More-
over, these E/e' thresholds were in keeping with the results of invasive
studies that showed that a E/e' ratio below 8 is an accurate indicator
of a normal LV ﬁlling pressure [32]. In the absence of an outcome-
driven age-speciﬁc diagnostic reference frame, averaging the 2.5 and
97.5 percentiles for the E/A ratio in subjects free from cardiovascular
diseases included FLEMENGHO [5] and EPOGH [6], and rounding the
resulting boundaries to the closest integer value, producedworking def-
initions of a normal E/A ratio. The lower boundaries of the age-speciﬁc
thresholds for the E/A ratio decreased approximately by 0.10 per decade
of age [5,6]. Absolute values of systolic and diastolic PV ﬂow velocity
and their ratio depend not only on diastolic LV properties, but also on
Table 2
Echocardiographic measurements by fourths of the distribution of HF1.
Characteristic Categories of the urinary HF1 biomarker
Limits, score b−1.639 −1.639 to−1.078 −1.077 to−0.489 ≥−0.488
Conventional echocardiography
Left atrial volume, mL 40.0 ± 11.4 42.1 ± 13.3 43.9 ± 14.8 44.8 ± 14.5
Left atrial volume index, mL/m2 21.6 ± 5.42 22.6 ± 6.28 23.2 ± 6.67 23.8 ± 6.83
Left ventricular mass, g 160.5 ± 43.5 169.4 ± 47.4 172.8 ± 50.7 183.6 ± 50.9*
Left ventricular mass index, g/m2 86.5 ± 18.8 91.0 ± 20.5* 91.7 ± 22.1 97.8 ± 23.5†
Doppler data
Deceleration time, ms 160.6 ± 30.6 158.3 ± 31.9 166.8 ± 33.9* 176.9 ± 43.2*
Isovolumetric relaxation time, ms 94.4 ± 14.6 96.6 ± 17.0 96.7 ± 14.1 100.3 ± 16.6*
E peak, cm/s 78.4 ± 14.9 78.3 ± 15.3 75.3 ± 16.5 71.2 ± 16.3*
A peak, cm/s 59.0 ± 16.0 61.2 ± 17.8 66.3 ± 17.0† 68.9 ± 15.8
E/A ratio 1.44 ± 0.51 1.39 ± 0.50 1.22 ± 0.45‡ 1.10 ± 0.40†
e' peak, cm/s 13.2 ± 3.65 12.2 ± 3.49† 11.2 ± 3.29† 10.0 ± 3.25‡
a' peak, cm/s 9.51 ± 2.22 9.88 ± 2.19 10.2 ± 1.98 10.5 ± 1.92
e'/a' ratio 1.56 ± 0.80 1.37 ± 0.67* 1.19 ± 0.52† 1.02 ± 0.47†
E/e' ratio 6.25 ± 1.60 6.88 ± 2.19† 7.08 ± 1.99 7.59 ± 2.23*
All ANOVA p values for differences in means across fourths of the HF1 distribution were signiﬁcant (≤0.0007). Signiﬁcance of the difference with the adjacent lower fourth:
* p ≤ 0.05; † p ≤ 0.01; ‡ p ≤ 0.001.
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tion, etc. [33]. These confoundersmight limit the use of PV ﬂow velocity
in the assessment of LV diastolic dysfunction, particularly, in general
population [33]. On the other hand, we measured the difference in
duration between the mitral A ﬂow and AR. Invasive studies [32,34]
demonstrated that a difference between the A wave and AR duration
of N0 ms is associated with a LV end-diastolic pressure of 20 mmHg or
greater with high sensitivity (82%) and speciﬁcity (92%). In our current
study, we checked differences in durations between the transmitral A
ﬂow and the reverse PV ﬂow during atrial systole (Ad b ARd + 10)
and/or LA volume index (≥28 ml/m2) to conﬁrm possible elevation of
the LV ﬁlling pressure.
In our current study, the E/e' ratio correlated positively with both
HF1 and HF2. These observations carry prognostic information. Indeed,
studies in patients with HF [35–37] or hypertension [38] demonstrated
that high E/e' predicted cardiac mortality and re-hospitalisation for HF
[35–37] or the risk of a cardiac event [38]. In the three HF studies
[35–37], the E/e' ratio was the only [35] or a strong [36,37] predictor
of the primary endpoint. Furthermore, a substudy to the Anglo-
Scandinavian Outcomes Trial (ASCOT) [38] involved 980 high-risk hy-
pertensive patients, free of cardiac disease at baseline and followed up
for a median of 4.2 years. In multivariable-adjusted Cox-proportionalTable 3
Multivariable-adjusted associations of echocardiographic measurements with 1-SD increases i
Characteristic Associations with HF1
Association size (95% conﬁdence interval)
Conventional echocardiography
Left atrial volume, mL −0.908 (−1.651 to−0.165)
Left atrial volume index, mL/m2 −0.473 (−0.850 to−0.096)
Left ventricular mass, g 0.118 (−2.568 to 2.805)
Left ventricular mass index, g/m2 0.697 (−0.662 to 2.056)
Doppler data
Deceleration time, ms 2.512 (0.013 to 5.012)
Isovolumetric relaxation time, ms −0.179 (−1.234 to 0.877)
E peak, cm/s −0.200 (−1.280 to 0.881)
A peak, cm/s −0.044 (−0.924 to 0.836)
E/A ratio −0.004 (−0.026 to 0.019)
e' peak, cm/s −0.204 (−0.351 to−0.057)
a' peak, cm/s −0.104 (−0.224 to 0.017)
e'/a' ratio −0.018 (−0.047 to 0.010)
E/e' ratio 0.145 (0.023 to 0.268)
Association were expressed for a 1-SD increase in the multidimensional classiﬁers HF1 and
treatment with inhibitors of the renin system (angiotensin-converting enzyme inhibitors or a
ventricular mass were additionally adjusted for body mass index and the Doppler data for bodhazards models, a unit rise in the E/e' ratio was associated with a
17% increment in risk of a cardiac event (95% conﬁdence interval,
1.05–1.29; p = 0.003) [38].
In the present study, HF1was not only associated with E/e', but with
e' as well. In a Chinese cohort of 174 hypertensive patients and 78 age-
matched controls, 19 patients (7.5%) experienced a fatal cardiac event
during 1.6 years of follow-up [39]. In adjusted analyses, e' was among
the strong predictors of cardiac mortality [39]. The positive association
of HF2 with the transmitral E/A ratio and the inverse correlation of
HF2 with a' peak mitral annular velocity at ﬁrst sight looks counter-
intuitive. However, Redﬁeld and colleagues [29] demonstrated that in
patients with severe diastolic LV dysfunction the transmitral A peak de-
creased resulting in a higher E/A ratio (so called pseudo-normalisation)
and that the a' peakwas lower than in subjects with normal diastolic LV
function. To ensure that our interpretation of the positive association
between the transmitral E/A ratio and HF2 was correct, we removed
the 96 patients with increased LV pressure from analysis. This weak-
ened the latter association to a non-signiﬁcant level. The above reports
[29,35–39] combined with the results of our current study highlight
that urinary proteomic biomarkers, such as HF1 and HF2, might predict
prognosis even in a population setting. Proving this hypothesis in the
follow-up of our FLEMENGHO cohort is therefore a research priority.n HF1 and HF2.
Associations with HF2
p Association size (95% conﬁdence interval) p
0.017 0.643 (−1.425 to 0.138) 0.11
0.014 −0.284 (−0.681 to 0.113) 0.16
0.93 0.481 (−2.326 to 3.289) 0.74
0.31 0.879 (−0.540 to 2.298) 0.22
0.049 3.971 (1.367 to 6.575) 0.003
0.74 −0.687 (−1.791 to 0.416) 0.22
0.72 0.603 (−0.525 to 1.732) 0.29
0.92 −0.106 (−1.025 to 0.813) 0.82
0.74 0.025 (0.002 to 0.049) 0.037
0.007 −0.082 (−0.236 to 0.072) 0.30
0.091 −0.152 (−0.278 to−0.026) 0.018
0.20 0.004 (−0.025 to 0.034) 0.77
0.020 0.174 (0.046 to 0.302) 0.008
HF2. All association sizes were adjusted for sex, age, mean arterial pressure, heart rate,
ngiotensin II type-1 receptor blockers), and use of β-blockers. Left atrial volume and left
y mass index and left ventricular mass index.
Table 4
Multivariable-adjusted odds ratios for a 1-SD increase in HF1 or HF2.
Characteristic Associations with HF1 Associations with HF2
Odds ratio(95% conﬁdence interval) p Odds ratio(95% conﬁdence interval) p
Impaired relaxation (n = 67) 1.38 (1.01 to 1.88) 0.043 1.24 (0.88 to 1.74) 0.22
Increased ﬁlling pressure (n = 96) 1.20 (0.88 to 1.63) 0.24 1.38 (1.00 to 1.90) 0.052
Impaired relaxation refers to patients with an abnormally low age-speciﬁc transmitral E/A ratio indicative without evidence of increased LV ﬁlling pressures (E/e'≤8.5). Increased ﬁlling
pressure refers to patientswith elevated LVﬁlling pressure (E/e'N8.5) and anE/A ratiowithin or below the normal age-speciﬁc range. Associationwere expressed for a 1-SD increase in the
multidimensional classiﬁers HF1 and HF2. All association sizes were adjusted for sex, age, bodymass index, mean arterial pressure, heart rate, left ventricular mass index, treatment with
inhibitors of the renin system (angiotensin-converting enzyme inhibitors or angiotensin II type-1 receptor blockers), and use of β-blockers.
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function should establish that the urinary proteome changes in parallel
with the echocardiographic ﬁndings and clinical outcomes.
Redﬁeld and coworkers categorised diastolic LV function as ranging
from normal to severe [29]. Mild diastolic dysfunction was impaired
relaxation without evidence of increased ﬁlling pressures; moderate,
was impaired relaxation associated with moderate elevation of ﬁlling
pressures or pseudo-normalﬁlling; and severe, was advanced reduction
in compliance with restrictive LV ﬁlling. In the present study, a 1-SD
increment in HF1 was associated with a 38% higher risk of impaired
relaxation, but not with a signiﬁcantly elevated risk of having an elevat-
ed LV ﬁlling pressure, whereas a 1-SD increment in HF2 was associated
with a 38% higher risk of increased LV ﬁlling pressure, but not with
impaired relaxation. These observations probably reﬂect the study
populations, from which the classiﬁers were derived. HF1 rests on a
case–control study including predominantly asymptomatic mild dia-
stolic LV dysfunction, whereas the cases from which HF2 was derived
predominantly consisted of patients hospitalised for overt HF.
In addition to HF1 and HF2, other correlates might help in screening
for diastolic LV dysfunction, including albuminuria [40], circulating NT-
proBNP [5], and the renal resistance index [41]. However, in our partic-
ipants randomly recruited from a general population the prevalence
of albuminuria was too low to be useful as a screening instrument.
Among asymptomatic participants, there is large overlap in the NT-
proBNP levels between categories of diastolic LV function. We did not
measure the renal resistance index, which is a measure of renal blood
ﬂow obtained by Doppler ultrasonography. Ciccone and coworkers
recently demonstrated in 250 out-patients with congestive heart failure
in stable condition that the resistance index predicted rehospitalisation,
progression to cardiac transplantation or heart failure death [41]. In the
further follow-up of our participants we are therefore measuring the
resistance index to test its prognostic value in relation to HF in largely
asymptomatic subjects recruited from a general population.
Under physiological conditions, the urinary proteome originates for
about 70% from the kidney and the urinary tract, while 30% is derived
from plasma [42]. Approximately 60% of the total mass of urinary
peptides and proteins consist of collagen fragments [22]. In our case–
control study, we demonstrated that most of the markers originated
from collagen [11]. Similarly, of the urinary peptides with known
amino-acid sequence that were included in HF2, 68.9% were collagen
fragments. The cardiac extracellular matrix predominantly consist of
ﬁbrillar collagen type I (85%) and type III (11%). In patients with HF,
the balance between collagen synthesis and degradation is disturbed
[43]. Diastolic LV dysfunction and HF associated with hypertension are
characterised by increased interstitial deposition and cross-linking of
type I collagen, a process that leads to LV stiffening [43]. However, our
current study cannot prove the cardiac origin of the urinary collagen
fragments that contribute to HF1 and HF2. For this reason, we are
currently pursuing two research avenues. First, we will run proteomics
on biopsies taken from explanted (diseased) and implanted (healthy)
hearts during cardiac transplantation surgery in an attempt to prove
that the urinary and tissue proteomic signatures are similar. Second,
we will link the urinary proteomic collagen fragments with circulatingbiomarkers of collagen synthesis and degradation [44]. Circulating bio-
markers of interest are the inhibitors ofmetalloproteinases that degrade
collagen, such as TIMP-1 and TIMP-4 [45]. The expression of these inhib-
itors is tissue speciﬁc [45]. Linking the urinary proteomewith these cir-
culating tissue-speciﬁc inhibitors will therefore help in differentiating
the cardiac vs. renal origin of the urinary collagen fragments.5. Study limitations
The present study must be interpreted within the context of its
limitations. Foremost, our ﬁndings arose from a cross-sectional anal-
ysis. Whether or not, the urinary proteomic biomarkers can predict
the course over time of diastolic LV dysfunction and associated car-
diovascular complications remains to be proven in longitudinal stud-
ies and in randomised clinical trials. However, the Olmsted County
study [29] in combination with our current ﬁndings suggest that
the urinary proteome might well be an early marker of incumbent
disease. Second, HF1 and HF2 still await validation against invasive
measures of diastolic LV function, such as the time constant of
isovolumetric relaxation (τ). However, several studies showed that
τ as assessed by transthoracic Doppler underestimates the invasively
measured τ, but that this slight underestimation is correctable by
accounting for left atrial or capillary wedge pressure [46,47]. Third,
228 of 973 people (23.4%) declined participation in our current
study. However, participants and non-participants had similar distri-
butions of female sex (51.3% vs. 51.3%; p = 0.99), age (49.8 vs.
47.3 years; p = 0.09), and previous cardiovascular disease (4.4% vs.
4.8%; p = 0.78). Fourth, we did not perform a Valsalva manoeuvre.
However, major limitations of the Valsalva manoeuvre are that not
every person can perform it adequately and that it is difﬁcult to
standardize. Moreover, its clinical value in distinguishing normal
from pseudo-normal mitral inﬂow substantially diminished since
TDI echocardiography of the mitral annulus allows a more precise
assessment of LV relaxation and estimation of LV ﬁlling pressures.
As proposed by experts [48], a Valsalva manoeuvre is only meaning-
ful if the echocardiographic assessment of diastolic LV function
leaves room for doubt, which was not the case in our participants.
Finally, before being clinically applicable our results need replication
in other population studies and in people of non-white ethnicity. On
the other hand, both HF1 and HF2 signiﬁcantly enhanced NRI differ-
entiating normal from abnormal diastolic LV function, but did not
substantially improve IDI. Our observations on IDI and NRI are not
contradictory. NRI is a categorical measure. It measures in how
many cases the probability of a positive diagnosis increases when
adding the biomarker to the model and vice versa in non-cases. IDI
is a continuous measure. It measures how much the probability of a
positive diagnosis in cases increases by adding the biomarker to
the model, and vice versa in the non-cases. Both metrics provide
complimentary information. Adding a biomarker to the model
might increase the probability of identifying a case, which means
an increase in NRI, but perhaps only to a limited extend, as reﬂected
by IDI.
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Our current study extends the ﬁndings of a previous case–control
study [11] to a larger population-based sample and suggest that the
urinary proteome is useful for early diagnosis of diastolic LV dysfunc-
tion. However, only prospective studies showing that the urinary prote-
ome predicts progression of diastolic LV dysfunction and randomised
clinical trials demonstrating that the urinary proteome changes in par-
allel with the response to treatment can turn this screening tool into a
clinically applicable modality. Having this research goal materialised
would be amajor step forward in view of the high prevalence of diastol-
ic LV dysfunction [5,6] and the associated risk of progression to overt HF
[29].
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